Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $16.50 Consensus Price Target from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIVGet Free Report) have received a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $16.50.

A number of analysts have weighed in on the company. Piper Sandler began coverage on Roivant Sciences in a research note on Friday, January 5th. They issued an “overweight” rating and a $20.00 price target on the stock. HC Wainwright decreased their target price on Roivant Sciences from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 14th. Wolfe Research started coverage on Roivant Sciences in a report on Thursday, February 15th. They issued an “outperform” rating and a $17.00 price target for the company. Guggenheim cut their price objective on shares of Roivant Sciences from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, November 15th. Finally, Bank of America upped their target price on shares of Roivant Sciences from $11.00 to $12.00 and gave the company a “neutral” rating in a report on Tuesday, January 2nd.

Get Our Latest Report on Roivant Sciences

Insider Buying and Selling

In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.92, for a total value of $1,058,694.00. Following the completion of the sale, the chief operating officer now directly owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Vivek Ramaswamy sold 3,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $11.05, for a total value of $33,150,000.00. Following the sale, the insider now owns 51,929,426 shares of the company’s stock, valued at approximately $573,820,157.30. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Eric Venker sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the transaction, the chief operating officer now owns 532,207 shares of the company’s stock, valued at $5,811,700.44. The disclosure for this sale can be found here. Insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors have recently bought and sold shares of ROIV. Vanguard Group Inc. lifted its holdings in shares of Roivant Sciences by 26.3% during the 4th quarter. Vanguard Group Inc. now owns 7,075,651 shares of the company’s stock valued at $79,460,000 after buying an additional 1,473,085 shares during the last quarter. Virtu Financial LLC acquired a new stake in Roivant Sciences in the 4th quarter worth approximately $136,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Roivant Sciences by 2.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,786,613 shares of the company’s stock worth $42,524,000 after buying an additional 74,131 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in shares of Roivant Sciences by 5.3% during the fourth quarter. Public Employees Retirement System of Ohio now owns 149,031 shares of the company’s stock worth $1,674,000 after buying an additional 7,459 shares during the last quarter. Finally, Dagco Inc. acquired a new position in shares of Roivant Sciences during the fourth quarter worth approximately $27,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Down 2.2 %

ROIV stock opened at $10.44 on Friday. The company’s 50 day moving average price is $10.95 and its 200 day moving average price is $10.49. The firm has a market capitalization of $8.41 billion, a price-to-earnings ratio of 2.01 and a beta of 1.37. Roivant Sciences has a fifty-two week low of $6.59 and a fifty-two week high of $13.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79.

Roivant Sciences (NASDAQ:ROIVGet Free Report) last announced its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. The company had revenue of $37.14 million for the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. On average, equities research analysts anticipate that Roivant Sciences will post -1.36 EPS for the current fiscal year.

About Roivant Sciences

(Get Free Report

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Further Reading

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.